What is already known
Increased STAT3 activation (in muscle) in multiple types of experimental
cancer cachexia; Enhanced FOXO1 activation in skeletal muscle triggered
the muscle atrophy by activation of downstream target genes, including
Atrogin-1 and MuRF1.